Multiparametric flow cytometry measurable residual disease monitoring provides clinical relevance in real-world adult acute myeloid leukaemia patients

Introduction: Monitoring measurable residual disease (MRD) is crucial in acute myeloid leukaemia (AML), but molecular methods are only viable for about one-third of patients. This study aimed to validate a single tube multiparametric flow cytometry MRD (MFC-MRD) assay for service implementation.